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Intervertebral disc (IVD) cell therapy with unconditioned 2D expanded mesenchymal stem cells (MSC) is a promising concept
yet challenging to realize. Differentiation of MSCs by nonviral gene delivery of growth and differentiation factor 5 (GDF5)
by electroporation mediated gene transfer could be an excellent source for cell transplantation. Human MSCs were harvested
from bone marrow aspirate and GDF5 gene transfer was achieved by in vitro electroporation. Transfected cells were cultured as
monolayers and as 3D cultures in 1.2% alginate bead culture. MSC expressed GDF5 efficiently for up to 21 days.The combination of
GDF5 gene transfer and 3D culture in alginate showed an upregulation of aggrecan and SOX9, twomarkers for chondrogenesis, and
KRT19 as amarker for discogenesis compared to untransfected cells.The cells encapsulated in alginate producedmore proteoglycans
expressed in GAG/DNA ratio. Furthermore, GDF5 transfectedMCS injected into an IVD papain degeneration organ culturemodel
showed a partial recovery of the GAG/DNA ratio after 7 days. In this study we demonstrate the potential of GDF5 transfectedMSC
as a promising approach for clinical translation for disc regeneration.
1. Introduction
Nonviral gene delivery is of great interest to stimulate cells
for a direct potential clinical application for a wide range of
musculoskeletal diseases. For repair and regeneration of the
spinal intervertebral disc, cells would be required to match
the native population in the intervertebral disc (IVD) niche.
The nucleus pulposus cells, at the centre of the disc, and
the annulus fibrosus cells, which populate the IVD “niches,”
are difficult to reproduce in the laboratory since the unique
markers to identify these cells are not known yet [1–4]. The
IVD niche is defined as a low pH, very dense extracellular
matrix consisting of collagen and glycosaminoglycan such as
aggrecan and relative low cellularity [5, 6]; therefore the disc
environment causes a major challenge for implanted cells
such as MSCs. One strategy if cells are to be transplanted
into a complex niche such as the IVD, which is populated by
highly specialised and perfectly adapted native cell popula-
tion, is to precondition the cells with some specialised growth
factor (GF) cocktail (which is not known yet) or by additional
mechanical stimuli [7]. Without doubt bone marrow derived
mesenchymal stem cells (MSCs) have been proposed in
many fields of musculoskeletal research because they can be
isolated relatively easily, show a fast proliferation, and hold
the potency to differentiate into differentmesenchyme tissues
[8, 9]. However, their usage for clinical applications has yet
to be determined as there are safety restrictions and quality
checks required before reimplantation into a patient [10, 11].
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The current surgical approach is either to remove the disc
(discectomy) and to fuse the adjacent vertebral bodies or to
add a metal cage in place [12]. Biological therapies to repair
the intervertebral disc are highly warranted. Growth factor
treatment is assumed to be a promising approach for IVD
regeneration. However, delivery to the target cells seems to
be hindered and mainly unsolved as it has been reported for
injection studies of BMP-2 in clinical study [13]. On the other
hand, approach to use hydrogel for regenerating the centre of
the disc has been proposed and studied numerous times with
moderate outcome, especially in biomechanical properties to
withstand mechanical loading in the long term [14]. Among
themethods tried for gene transfer so far adenoviral methods
[15, 16] have been widely used, which have high efficiency
but are not very much accepted in the translational research
perspective [17]. Growth and differentiation factor 5 (GDF5,
syn. BMP14 or CDMP1) has been shown to be a key factor
to push primary hMSCs towards an intervertebral-disc-like
phenotype [18, 19], but it was also confirmed as a stimulating
and a strong regenerative factor for disc cells in vitro [20]
and in vivo in a rabbit IVD annulus stab degeneration
model [21]. Further evidence for key importance of GDF5
for low back pain comes from a population based study to
identify linkage disequilibrium of a single-nucleotide poly-
morphism [22]. Recombinant human rhGDF5 is currently
under investigation as a drug to regenerate the IVD in a ran-
domised phase-II clinical trial (http://www.clinicaltrials.gov/
case NCT01124006). However, exogenous injection of GDF5
is a very costly treatment with not a very endurable scenario
unless it is delivered with a technique, which can offer
sustained levels to achieve therapeutic benefits. The question
of drug delivery to cells is unsolved as recently suggested
by Carragee et al. for the case of direct injection of BMP2
as a spinal fusion enhancer [13]. Thus, we were interested
to test nonviral gene therapy approach by direct delivery of
the gene via electroporation of primary hMSCs and to test
whether these would differentiate into intervertebral-disc-
like precursor cells by overexpression of GDF5. Thus, we
performed in vitro electroporation mediated gene transfer
of GDF5 to primary hMSCs and injected them into an
intervertebral disc explant model, with an aim to achieve disc
regeneration.
2. Materials and Methods
2.1. Cell Source and Expansion. Human bone marrow was
obtained from 12 patients aged 20–60 undergoing hip or spine
surgery after written consent (Table 1). The procedure was
approved by the Ethics Office of the Canton of Bern (KEK
# 187/10). Human mesenchymal stem cells (hMSCs) were
amplified from the mononuclear cell fraction after density
gradient centrifugation (Histopaque-1077, Sigma-Aldrich,
Buchs, Switzerland) by selection for plastic adherence for 1-2
passages.The hMSCs were expanded using Dulbecco’s Modi-
fied Eagle Medium (DMEM), low glucose, GlutaMAX, and
pyruvate with 10% FBS, 100 𝜇g/mL penicillin, 100UI/mL
streptomycin, and 2.5 ng/mL bFGF-2 [23].
Table 1: List of donors used for hMSC expansion. All cells were
obtained with ethical approval (KEK 187#10) from bone marrow
aspirates of the vertebral body of patients undergoing spinal surgery.
ID Site of aspiration Gender Age
Patient 49 — Male 51
Patient 50 — Female 77
Patient 51 Th11, Th12 Female 38
Patient 52 L1 Female 79
Patient 53 — Female 86
Patient 54 Th11, L1 Female 73
Patient 55 Th10, Th12 Male 61
Patient 56 Th11, L1 Female 58
Patient 57 Iliac Crest Female 81
Patient 58 Th5, Th6 Female 54
Patient 59 Th10, Th12 Female 80
Patient 60 Th10, L2, L3 Female 81
Th: thoracic vertebral body, L: lumbar vertebral body.
2.2. Characterization of hMSCs for Presence of Stromal CD
Marker Expression. The isolated human mesenchymal stem
cells were characterised for their surface markers. Two
independent MSC populations (2 different donors, patient
59 and 60) were randomly selected and analysed for CD105,
CD44, CD29, CD90, and CD45 (Abcam, Cambridge, MA,
USA) by flow cytometry on a FACS LSRII (BD Biosciences
Inc., Brussels, Belgium).The results for each CDmarker were
compared to unstained cells and isotype controls.
2.3. Nucleofection of Cells. The transfection-ready plasmid
RG207105 Human cDNAORF Clone of GDF5 (NM 000557)
was selected as a vector. The plasmid contains a CMV
promoter and a fusion protein of GDF5 including a GFP-tag
(OriGene Technologies Inc., Rockville, MD, US) (Figure 1).
Prior to electroporation RG207105 was amplified in E. coli
with positive selection in presence of ampicillin (Sigma-
Aldrich, St. Louis, USA) and purified using QuickLyse
Miniprep Kit according to the instructions of the manu-
facturer (Qiagen Inc., Basel, Switzerland). The ORF of the
sequence of GDF5 was back-checked for accumulation of
point mutations resulting from cloning using direct DNA
sequencing of the insert of RG207105 (Microsynth, Balgach,
Switzerland) using the provided DNA primers. hMSCs were
electrophoresed by Nucleofector technology (Amaxa, Lonza,
Basel, Switzerland) using Lonza’s optimized protocol U-
23 (the protocol C-17 revealed low transfection efficiency
of ∼10% transfected cells) and the mesenchymal stem
cell Nucleofector solution (VPE-1001, Amaxa, Lonza Inc.),
which provided a protective environment and allowed high
transfection efficiency and cell viability. About 500k cells
were transfected per reaction, centrifuged, resuspended in
Nucleofector solution, and mixed with 2𝜇g of plasmid DNA
according to the instructions of the manufacturers. Directly
after the electrical pulses, prewarmed DMEM LG, 10% FBS
was added to the cuvette and the cell suspension was seeded
into a 6-well or 12-well plate.
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Figure 1: Plasmid map of pCMV6-AC-GFP vector containing
the true gold ORF of human GDF5 (GenBank accession number
NM 000557) with C-terminal TurboGFP.
2.4. Immunohistological Staining. Cells growing in mono-
layer were stained for the presence of intracellular GDF5.
Transfected cells were seeded onto glass cover slips in a
6-well plate and cultured for 14 days. Then the cells were
initially fixed in 4% paraformaldehyde (PFA) directly on
the 6-well plate. Cells were then made permeable by incu-
bation with 0.1% Tween in PBS. Cells were preincubated
for 1 h with 1xPBS and 10% FCS to block the unspecific
staining, washed, and then incubated with the primary rabbit
polyclonal antibody (GeneTex, Ivine, CA, US, cat. Number
GTX113580) against GDF5 at a dilution of 1 : 200 for 1 h. After
thoroughly washing the cells the secondary red fluorescently
labelled antibody (Abcam, ab6939) was amended at a dilution
of 1 : 1000. The stained cells on the glass cover slip were
mounted on a glass slide with 1 droplet of mounting medium
for fluorescence with DAPI (Vectashield, H-1200, Reactolab,
Servion, Switzerland). Images were taken with a fluorescence
microscope AF 6000 LX from Leica (Wetzlar, Germany).
2.5. 3D Alginate Culture. Electroporated MSCs were tryp-
sinized after 1 week of monolayer culture (expansion)
using 0.5% EDTA-Trypsin (Gibco, Life Technologies, Basel,
Switzerland). Cells were washed in phosphate buffered
saline (PBS) and seeded in 1.2% alginate with a density of
2 × 106 cells/mL and pressed through a syringe with 22G
needle. This procedure allowed to create ∼30 𝜇L beads which
were formed by dropping the alginate into a 102mM CaCl
2
solution. Cells were then grown in high glucose DMEM
GlutaMAX containing pyruvate, 10% FBS, 1% penicillin/
streptomycin (Gibco, Life Technologies, Invitrogen, Basel,
Switzerland) in the absence of dexamethasone. Beads were
snap-frozen on days 7, 14, and 21 and were analysed for gene
expression and GAG/DNA content.
2.6. Relative Gene Expression Analyses. For gene expression,
cells were either directly lysed or alginate beads were flash-
frozen in liquid N
2
. Beads were then shattered into powder
under liquid N
2
and total RNA was extracted from the
constructs with TRI reagent (Molecular Research Center)
using a modified TRIspin method [24]. Total RNA (100–
200 ng) was used for reverse transcription (RT) and subse-
quent PCR (RT-PCR) using gene-specific primers and probes
[25, 26]. Reverse transcription was performed with Bio-Rad
reverse transcription reagents (Bio-Rad, Glattbach, Switzer-
land). Real-time PCR was performed on an IQ-5 RT-PCR
system (Bio-Rad, Reinach, Switzerland) using SYBR Green
technology. Oligonucleotide primers (all from Microsynth,
Balgach, Switzerland) have been designed with Primer Bea-
con Designer Software (Premier Biosoft Inc., Palo Alto, CA,
USA) using nucleotide sequences taken from the GenBank
database (Table 2). RT-PCR was quantified using the IQ-5
cycler software (Bio-Rad, Basel, Switzerland). A threshold
value of fluorescence was set in the exponential phase of
the amplification, and the number of PCR cycles needed for
each sample to reach that level was recorded as the C
𝑡
value
[27]. Gene expression was quantified by ΔC
𝑡
values using
the relative quantificationmethod (Applied Biosystems: User
Bulletin number 2 ABI Prism 7700 Sequence Detection
System, 2001), which normalises C
𝑡
values relative to the
gene expression of a house-keeping gene (e.g., ribosomal
18S). ΔΔC
𝑡
values at day seven will then be estimated relative
to day 0 and transformed into relative mRNA values using
the formula 2-ΔΔC
𝑡
[28]. We screened the relative gene
expression of major anabolic genes: aggrecan, collagen I,
collagen II; and other recently published IVD marker genes
[2, 18, 29] (Table 2).
2.7. GAG/DNA Ratio. Three beads or the IVD tissues were
digested overnight at 60∘C with 125𝜇g/mL papain from
papaya latex (P-3125, Sigma-Aldrich) in 5mM Cysteine-
HCl (30119, Fluka, Buchs, Switzerland), 55mM Na-Citrate
(71406, Fluka), 150mM NaCl (71380, Fluka), and 5mM
EDTA (03685, Fluka). Glycosaminoglycan (GAG) content
was quantified by 1,9-dimethylmethylene blue (DMMB)
binding assay. DMMB binds to GAG at a pH of 1.5 (but
alginate is believed to be protonated at pH 1.5) and absorp-
tion can be measured at a wavelength of 600 nm. Stan-
dard curve is done with a dilution of chondroitin sulfate
(C9819, Sigma-Aldrich) in papain buffer, described above.
The amount of DNAwas determined by Quant-iT PicoGreen
dsDNAReagent (P11496, Invitrogen, Life TechnologiesCorp.,
Basel, Switzerland), following the manufacturer’s protocol
with a high-range standard curve of Lambda DNA stan-
dard (P11496, Invitrogen Life Technologies Corp., Basel,
Switzerland) [30, 31]. Fluorescence was measured using
a spectrofluorometer reader (SpectraMax, M5, Molecular
Devices, USA) at excitation 487 nm and emission at 525 nm,
with a cutoff at 515 nm.
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Table 2: Primer list used for RT-PCR.
Abbreviation Gene name Forward Reverse
Hs 18S Reference gene CGA TGC GGC GGC GTT ATT C TCT GTC AAT CCT GTC CGT GTC C
Hs ACAN Aggrecan CAT CAC TGC AGC TGT CAC AGC AGC ACT ACC TCC TTC
Hs COL1 Collagen1 A2 GTG GCA GTG ATG GAA GTG CAC CAG TAA GGC CGT TTG
Hs COL2A1 Collagen 2 A1 AGCAAGAGCAAGGAGAAG GGGAGCCAGATTGTCATC
Hs SOX9 SRY hox gene 9 GAG ACT TCT GAA CGA GAG GGC TGG TAC TTG TAA TCC
Hs KRT19 Keratin 19 TGT GTC CTC GTC CTC CTC GCG GAT CTT CAC CTC TAG C
Hs GDF5 Growth and differentiation factor 5 (GDF5) ATCAGCATCCTCTTCATTGACTCT ACACGACTCCACGACCAT
Hs GFP Green fluorescent protein ATGACCAACAAGATGAAGAG AAGTGGTAGAAGCCGTAG
2.8. In Vitro Organ Culture Model and hMSC Injection. In
order to test the feasibility of cell survival in the IVD environ-
ment the transfected cells were injected into an established
organ culture model. Bovine coccygeal intervertebral discs
were harvested from a local abattoir according to regulations
of the local authorities. Intervertebral discs were prepared
for organ culture as described previously using Ringer solu-
tion and a jet lavage spraying technique to enable nutrient
diffusion for organ culture [32, 33]. The prepared discs
were then injected with 60 i.U. of papain (Sigma, Aldrich)
using a 25G needle in the center of the IVD as described
previously and incubated for 7 days at 37∘C in a standard
incubator and HG-DMEM and 5% FCS in free-swelling
conditions. The cells were taken up at a density of 4M
cells/mL in soft Q-Gel polyethylene glycol (PEG) hydrogel
(Ref 1004, MMP-degradable matrix without RGD, Q-Gel SA,
Lausanne, Switzerland). After the cavity has been formed
with papain digestion about 200 𝜇L, thus about 200 k hMSCs
were injected into the cavity using a 22G needle and a 1mL
syringe (BD Bioscience, Allschwil, Switzerland). There were
three groups of cells injected: (1) untransfected MSCs, (2)
transfectedwith a control plasmid (pmaxGFP,Amaxa, Lonza,
Basel, Switzerland), and (3) MSC+pRG207105 containing the
GDF5 sequence. Additionally, there was a hydrogel only
control and an untreated organ culture control disc. The
IVDs with the injected hydrogel/cell mixture were then incu-
bated for 7 days without loading in special designed culture
chambers [33]. After incubation the IVDs were dissected and
the hydrogel/cell mixture was inspected macroscopically and
microscopically. The inner and outer annulus fibrosus of the
IVD was subjected to analysis of GAG and DNA.
2.9. Statistics. The relative gene expression data were tested
against a hypothetical mean of 1.0, which were the untrans-
fected sham cells using a nonparametric Wilcoxon signed-
rank test due to the nonnormal distribution of the data. All
calculations were done in Prism 6.0 c (Palo Alto, CA, USA).
For the GAG/DNA ratio we tested with an unpaired t-test
assuming equal standard deviations and a one-sided tail.
3. Results
3.1. CD Marker Expression of hMSCs. Both selected donors
showed positive staining for the markers CD90, CD44 and
for one donor CD105 was also slightly positive. Negative
staining was seen for both donors in the CD markers 45
(see Supplementary Figure 1 available online at http://dx.doi)
.org/10.1155/2013/326828).
3.2. In Vitro Transfection Assays in 2D and 3D. MSC
expressed GDF5 efficiently for up to 3 weeks. The fused pro-
tein could be found as a green fluorescence (GFP-tag), moni-
tored under a green fluorescentmicroscope up to three weeks
after transfection and could also be detected with the specific
antibody against GDF5 (Figures 2(c) and 2(d)). The protocol
U-23 produced significantly more green cells than C-17
(Figures 2(a) and 2(b)). The combination of GDF5 gene
transfer and 3D culture in alginate showed a significant
upregulation of SOX9 as a marker for chondrogenesis and
KRT19 as a marker for discogenesis compared to untrans-
fected cells (Figure 3).The hMSCs which were electroporated
and then encapsulated in alginate and grown for 14 days
tended to produce more proteoglycans in culture (GAG per
DNA); however, this was not statistically significant, 𝑃 =
0.196 (Figure 4).
3.3. 3D Organ Culture. The incubation of cells and hydrogel
inside the 3D organ culture revealed by macroscopic inspec-
tion that the PEG hydrogel shrunk considerably in volume
to around 20% of its initial volume. However, the cells could
be still detected in the hydrogel as imaged with fluorescent
microscopy of the pmaxGFP transfected cells (Figure 5).
The GAG/DNA ratio of papain digested discs was reduced
considerably by almost a factor of 10 (Figure 6). However, in
the group with the hMSCs, which were transfected with the
RG207105 plasmid, a partial recovery of the GAG/DNA ratio
could be observed (Figure 6).
4. Discussion
4.1. Phenotype of hMSCs. Our GDF5 transfected MCS dif-
ferentiated towards an IVD-like phenotype. We found a
significant upregulation of ACAN, SOX-9, and interestingly
also KRT19. KRT19 has been recently identified as a potential
marker for a discogenic phenotype [18, 19], and this “marker
behaviour” of KRT19 could be confirmed in our study.
However, the fact that collagen type 2 did not show any
increase this might be a typical response of the growth factor
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Figure 2: (a) and (b) pmaxGFP-transfected hMSC 48 hours after C-17 (a) or U-23 (b) electroporation using the Amaxa nucleofector. (c)
and (d) GDF5 expression of transfected and control hMSC after 14 days of monolayer culture, anti-GDF5 antibody from GeneTex. Blue: cell
nucleus stained by DAPI, green: translated GFP, red: intracellular GDF5. (c) Cell population at a resolution of 20x or (d) close-up (68x) hMSC
transfected with RG207105, inlet in C = sham control.
Monolayer
G
en
e e
xp
re
ss
io
n 
re
lat
iv
e t
o 
co
nt
ro
l c
el
ls
AC
A
N
CO
L1
CO
L2
A
1
SO
X9
KR
T1
9
G
D
F5
10
−1
10
0
10
1
10
2
10
3
10
4
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
(a)
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
∗
3D culture in alginate beads
AC
A
N
CO
L1
CO
L2
A
1
SO
X9
KR
T1
9
G
D
F5
G
en
e e
xp
re
ss
io
n 
re
lat
iv
e t
o 
co
nt
ro
l c
el
ls
10
−1
10
0
10
1
10
2
10
3
10
4
(b)
Figure 3: Relative gene expression to untransfected cells after 7, 14, and 21 days (three time points) in monolayer culture (a) and (b) in 3D
cell culture using 1.2% alginate beads; gray bars correspond to state of day 0 cells (day 7 in monolayer culture). Bars represent min. to max.
with a line at the mean. N = 4 ± SEM. ∗∗∗ denotes significantly different from 1 (untransfected cells) with 𝑃 < 0.0001.
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Figure 4: Glycosaminoglycan (GAG)/DNA ratio of alginate bead
culture comparing transfected and untransfected cells over time.
Figure 5: Q-Gel hydrogel with GFP expressing hMSCs (pmaxGFP)
imaged with fluorescent microscope recovered from the center of
the disc after 7 days of bovine intervertebral disc organ culture.
GDF5 in absence of dexamethasone. Previous studies [18, 19]
used dexamethasone in combination with the growth factors
GDF5 and TGF-𝛽, and dexamethasone has been shown to
have stimulatory effects on its own [34, 35] in absence of
TGF-𝛽 or other BMP-related cytokines. Thus, the current
lack of collagen type 2 expression could be explained due to
lack of dexamethasone or due to differential expression of
GFP-tagged fusion protein compared toGDF5 alone (without
GFP). Previous studies have demonstrated stimulatory effect
on in vitro intervertebral disc cells [20, 36]. A similar
approachwas also undertaken byWang et al. [16] but using an
adenovirus as a vector.We also tested the plasmid pZS2GDF5,
which Wang et al. [16] used previously. The relative gene
expression results (data not shown) were similar as with the
GFP-tagged plasmid RG207105. Interestingly the production
of GAG increased in 3D cultures compared to the monolayer
culture. GDF5 is an interesting candidate for gene therapy
for the intervertebral disc as it has been shown in a rabbit
annulus-puncture degeneration model [21].
The hMSCs utilized in our study are predominately from
women donors (Table 1) and it should be mentioned that
the outcome of donor variation might be biased. It has been
recently reported in primary intervertebral disc cells [37]
that only male nucleus pulposus cells (NPC) responded to
testosterone present in the culturemedia.However, in hMSCs
Bertolo et al. [37] did not find any sex-dependent effects of the
donor variation. Moreover, a sex-dependent polymorphism
of estrogen receptor alpha PvuII restriction site has been
recently associated with the higher basal osteoblast differen-
tiation capacity of MSCs [38].
The outcome of the organ culture feasibility study
revealed that the transfected cells could have some potential
to recover the GAG/DNA ratio (Figure 6), especially in the
inner AF, the region where a cavity was created in the disc
degeneration model. It is yet unclear how the phenotype
of the injected hMSCs is progressing in the tested PEG
hydrogel and the disc environment. Due to problems to
extract enough RNA for RT-PCR reaction and/or problems
from the PEG hydrogel we were unable to demonstrate the
actual phenotype of hMSCs after 3D organ “coculture” of the
cells. However, we speculated that the phenotype might have
been even improved since the GAG/DNA ratio increased
quite dramatically from 9.0 to 55.2 (Figure 6).
4.2. The Action of GDF5 during Musculoskeletal Development.
There have been a number of studies performed to study
the function of GDF5 onto the development of the skeletal
system.
In a wild type mouse the phenotype of brachypodism
appears in the E12.5 state of embryonic development. At
this point the first cartilage condensations are formed, which
then are reduced in the brachypod (bp) mouse and also the
cartilage differentiation is delayed. However overexpression
of GDF5 in the mouse [39] and chicken [40] leads to an
increased cartilage condensation secondary to thickening
of the cartilage Anlagen. These studies showed that GDF5
regulates the initiating cartilage formation with induction
of cell adhesion and condensation of mesenchymal cells
followed by the differentiation towards chondrocytes. In the
course of development GDF5 controls the proliferation of
those chondrocytes in the perichondrium and therefore has
an impact on the growth and shape of the developing bones.
GDF5 is also expressed in the future articular zones, where it
has a high influence on the development of the joints [41, 42].
How essential GDF5 is for the development of the extrem-
ities can easily be seen on patients with a loss of function in
GDF5. A heterozygous loss of function mutation in GDF5
leads to a malformation of the hands, the brachydactyly
type C [43]. Homozygous GDF5 loss of function mutation
leads to a more complex alteration of the skeleton also
known as the group of acromesomelic chondrodysplasia.
They are clinically classified asGrebe type,Hunter-Thompson
type, and the DuPan type. Patients with Grebe type show
the most severe form of alteration of the skeleton with
a high degree dwarfism, extremely short extremities and
rudimentary finger Anlagen [44]. Patients with the Hunter-
Thompson type feature a similar phenotype however with
a less severe manifestation [45]. The DuPan type is termed
the mildest type of the acromesomelic chondrodysplasia. It
implies as a clinical feature a fibular hypoplasia, which leads
to severe disability of normal walking [46].
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Figure 6: Glycosaminoglycan (GAG)/DNA ratio of outer and inner annulus fibrosus (AF) after 7 days of free-swelling organ culture of bovine
intervertebral discs. Please note the difference between untransfected hMSC, control, pmaxGFP, and RG207105 transfected cells. The GDF5
overexpressing cells are pushing partially GAG/DNA ratio back in bovine IVD organ culture.
5. Conclusions
The present study could reproduce partially the stimulating
effects of overexpressing GDF5 of GAG/DNA ratio obtained
in previous studies using an adenoviral delivery system for
nucleus pulposus (NP) cells or NP explants [16, 20, 40]. Here,
we further show that overexpression of GDF5 will switch
on expression of ACAN but not necessarily collagen type 2
in the absence of dexamethasone in the medium. However,
this specific gene expression profile, which is induced by
the GF, makes GDF5 a possible target candidate for the
production of therapeutic cells grown from expanded hMSCs
and reimplanted into the degenerated disc of a low back
pain patient. Upcoming studies will investigate efficiency
of nonviral gene transfer of multiple genes (i.e., GDF5 in
combination with TGF-𝛽) and combined effect of gene
therapy and environmental conditions such as soluble GFs or
hypoxia.
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